No Data
MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update
FDA Is Said to See "Path Forward" for Ecstasy-based Drug
Bright Minds Rally Ends as Psychedelic Stocks Extend Volatility
Leerink Partners Initiates Mind Medicine(MNMD.US) With Buy Rating, Announces Target Price $20
Mind Medicine: A Strong Buy on Financial Health and Growth Prospects
Mind Medicine Assumed With an Outperform at Leerink